The current pharmaceutical industry landscape creates some interesting opportunities for CDMOs to grow and develop.

Increasingly complex products, evolving patient needs and regulatory updates are all changing the way contract partners are doing business.

In the second part of Manufacturing Chemist’s contract manufacturing roundtable, our Executive Vice President of Corporate Development, Mark Quick, discusses the trends in the industry and how increasingly complex pharmaceutical products, evolving patient needs and regulatory updates are all changing the way contract partners are doing business.

Read the full article here

You can also read the first part of the roundtable here

Manufacturing Chemist, May issue 2017